Search for: "King v. Merck "
Results 21 - 40
of 53
Sorted by Relevance
|
Sort by Date
9 Jan 2015, 5:32 am
Merck & Co. [read post]
28 Sep 2016, 8:39 am
Post Grant Admin: Merck & Cie, et al. v. [read post]
5 Sep 2016, 6:46 pm
Post Grant Admin: Merck & Cie, et al. v. [read post]
9 Aug 2012, 5:00 am
Merck (Vioxx) Trial2006-05-08 Doherty v. [read post]
12 Oct 2007, 7:03 am
Mar. 8, 2006); King v. [read post]
9 Mar 2011, 3:00 am
Bayer AG (FDA Law Blog) (Patent Docs) Dexilant (Dexlansoprazole) – US: Takeda files patent infringement suit against Handa following Para IV certification filing (Patent Docs) EpiPen – US: Orange Book patent delisting counterclaim raised in 505(b)(2) application patent infringement litigation; decision could provide guidance on drug delivery system patent listability: King Pharmaceuticals v Intelliject (FDA Law Blog) Fentora (Fentanyl) – US: Cephalon… [read post]
2 Mar 2012, 6:52 am
Merck (Vioxx) Trial2006-05-08 Doherty v. [read post]
21 Dec 2017, 7:09 am
This work will encompass multiple research projects with the current proposals looking at: the role of price differentials, sector specific impacts and enforcement impacts.BREAKING: CJEU holds that SPCs cannot be obtained on the basis of an "end of procedure notice" pursuant to Article 3(b) SPC RegulationMr Justice Arnold referred two questions to the CJEU on the SPC Regulation in Merck Sharp & Dohme v Comptroller-General of Patents [2016] EWHC… [read post]
25 Jan 2010, 5:00 am
Conversely, if plaintiffs could import the “fraud on the market” presumption of reliance into non-securities contexts – such as consumer fraud/common-law fraud/warranty litigation against our drug/device clients – an invasion of class actions would follow like night follows day.It’s hardly surprising that, because we don’t want class actions certified against our clients, we’re not big fans of “fraud on the market,” and we want to remain see it… [read post]
29 Jul 2009, 6:45 am
Tafas v Doll (Patent Docs) US: For stem cells, it seems that conception is enough: University of Pittsburgh v Hedrick (Patent Docs) (Patents4Life) US: General Accountability Office report on Bayh-Dole: Leverage to promote commercialisation of federally-funded inventions (PatentBIOtech) US: AlphaVax seeks review of BPAI decision awarding priority of invention to Novartis in interference between patents related to Alphavirus (Patent Docs) US: Teva, Taro lobby US legislators on… [read post]
15 Dec 2014, 7:25 am
* Oracle v Google: are certain elements of the Java platform entitled to copyright protection? [read post]
7 Nov 2014, 5:52 am
King-Washington v. [read post]
14 Feb 2011, 7:31 am
On January 28, 2011, the Delaware Supreme Court clarified in King v. [read post]
12 Dec 2017, 11:02 am
Mermeren v Fox. [read post]
8 Feb 2017, 3:09 am
King Drug Company of Florence, Inc., et al., No. 15-1055 (antitrust reverse payment – appeal from the 3rd Cir.) [read post]
16 Jan 2017, 5:44 pm
King Drug Company of Florence, Inc., et al., No. 15-1055 (antitrust reverse payment – appeal from the 3rd Cir.) [read post]
12 Dec 2008, 7:00 am
EU: European Commission preliminary report on its inquiry into competition in the pharmaceutical sector (Spicy IP) (Intellectual Property Watch) (Patent Baristas) EU: Enlarged Board of the EPO denies WARF’s patent application directed to human embryonic stem cells (Patent Docs) US: Patent Office assault on pharma industry (PLI) US: Proponent of gene patent ban Rep Xavier Becerra to leave Congress (Patent Docs) US: Merck & Co starts generic arm BioVentures to copy biologic… [read post]
17 Feb 2010, 5:10 am
Merck, Sharp & Dohme Corp. [read post]
18 Sep 2016, 6:03 pm
Post Grant Admin: Merck & Cie, et al. v. [read post]
27 Feb 2009, 5:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Evista (Raloxifene) – US: CAFC affirms extension of 30-month stay against Teva’s generic Evista: Eli Lilly & Co v Teva Pharmas. [read post]
